Related Experiment Video
Updated: Feb 21, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Edaravone Attenuates the Proinflammatory Response in Amyloid-β-Treated Microglia by Inhibiting NLRP3
Background/Aims:
Microglial activation is an important pathological feature in the brains of patients with Alzheimer's disease (AD), and amyloid-β (Aβ) peptides play a crucial role in microglial activation. In addition, edaravone (EDA) was recently shown to suppress oxidative stress and proinflammatory cytokine production in APPswePS1dE9 (APP/PS1) mice. However, the mechanism by which EDA inhibits the Aβ-induced proinflammatory response in microglia is poorly understood.
Methods:
The mitochondrial membrane potential (∆ψm) was evaluated using JC-1 staining. Intracellular reactive oxygen species (ROS) and mitochondrial ROS levels were detected using CM-H2DCFDA and MitoSOXTM Red, respectively. The levels of CD11b, NLRP3, pro-caspase-1 and manganese superoxide dismutase (SOD-2) were observed by western blotting, and the levels of interleukin-1beta (IL-1β) in culture supernatants were quantified using an ELISA kit.
Results:
Aβ induced microglia activation and mitochondrial dysfunction. In addition, mitochondrial dysfunction was associated with ROS accumulation and activation of the NLRP3 inflammasome. Importantly, Aβ induced activation of the NLRP3 inflammasome, leading to caspase-1 activation and IL-1β release in microglia. Moreover, EDA obviously attenuated the depolarization of ∆ψm, reduced mitochondria-derived ROS production and increased SOD-2 activity, resulting in the suppression of NLRP3 inflammasome-mediated IL-1β secretion in Aβ-treated microglia.
Conclusion:
EDA is a mitochondria-targeted antioxidant and exhibits anti-inflammatory effects on Aβ-treated microglia.
Insights
Edaravone (EDA) reduces inflammation in Alzheimer's disease (AD) models by targeting mitochondria. It suppresses amyloid-beta (Aβ)-induced microglial activation and the release of inflammatory cytokine IL-1β.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglial activation by amyloid-beta (Aβ) is central to Alzheimer's disease (AD) pathology.
- Edaravone (EDA) shows potential in reducing oxidative stress and inflammation in AD mouse models.
- The precise mechanism of EDA's anti-inflammatory action on Aβ-stimulated microglia remains unclear.
Purpose of the Study:
- To elucidate the mechanism by which edaravone (EDA) inhibits amyloid-beta (Aβ)-induced inflammation in microglia.
- To investigate the role of mitochondrial dysfunction and NLRP3 inflammasome activation in Aβ-induced microglial responses.
- To evaluate EDA's effects on mitochondrial function and oxidative stress in the context of Aβ exposure.
Main Methods:
- Assessed mitochondrial membrane potential (∆ψm) using JC-1 staining.
- Measured intracellular and mitochondrial reactive oxygen species (ROS) using fluorescent probes.
- Analyzed protein levels of CD11b, NLRP3, pro-caspase-1, and SOD-2 via western blotting.
- Quantified IL-1β release using ELISA.
Main Results:
- Amyloid-beta (Aβ) triggered microglial activation and mitochondrial dysfunction, correlating with ROS accumulation and NLRP3 inflammasome activation.
- Aβ-induced NLRP3 inflammasome activation led to caspase-1 activation and IL-1β release.
- Edaravone (EDA) treatment attenuated mitochondrial depolarization, reduced ROS production, enhanced SOD-2 activity, and suppressed NLRP3 inflammasome-mediated IL-1β secretion.
Conclusions:
- Edaravone (EDA) acts as a mitochondria-targeted antioxidant.
- EDA demonstrates significant anti-inflammatory effects on microglia exposed to amyloid-beta (Aβ).
- EDA may offer a therapeutic strategy for mitigating neuroinflammation in Alzheimer's disease.
